These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29107004)

  • 21. What do we mean by identifiability in mixed effects models?
    Lavielle M; Aarons L
    J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):111-22. PubMed ID: 26660913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GenSSI: a software toolbox for structural identifiability analysis of biological models.
    Chiş O; Banga JR; Balsa-Canto E
    Bioinformatics; 2011 Sep; 27(18):2610-1. PubMed ID: 21784792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifiability of PBPK models with applications to dimethylarsinic acid exposure.
    Garcia RI; Ibrahim JG; Wambaugh JF; Kenyon EM; Setzer RW
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):591-609. PubMed ID: 26194069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Global identifiability of nonlinear models of biological systems.
    Audoly S; Bellu G; D'Angiò L; Saccomani MP; Cobelli C
    IEEE Trans Biomed Eng; 2001 Jan; 48(1):55-65. PubMed ID: 11235592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The deterministic identifiability of nonlinear pharmacokinetic models.
    Godfrey KR; Fitch WR
    J Pharmacokinet Biopharm; 1984 Apr; 12(2):177-91. PubMed ID: 6491900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural identifiability of systems biology models: a critical comparison of methods.
    Chis OT; Banga JR; Balsa-Canto E
    PLoS One; 2011; 6(11):e27755. PubMed ID: 22132135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. dOFV distributions: a new diagnostic for the adequacy of parameter uncertainty in nonlinear mixed-effects models applied to the bootstrap.
    Dosne AG; Niebecker R; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):597-608. PubMed ID: 27730481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose response signal detection under model uncertainty.
    Dette H; Titoff S; Volgushev S; Bretz F
    Biometrics; 2015 Dec; 71(4):996-1008. PubMed ID: 26228796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identifiability and numerical algebraic geometry.
    Bates DJ; Hauenstein JD; Meshkat N
    PLoS One; 2019; 14(12):e0226299. PubMed ID: 31834904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identifiability and online estimation of diagnostic parameters with in the glucose insulin homeostasis.
    Eberle C; Ament C
    Biosystems; 2012 Mar; 107(3):135-41. PubMed ID: 22100871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An approach for identifiability of population pharmacokinetic-pharmacodynamic models.
    Shivva V; Korell J; Tucker IG; Duffull SB
    CPT Pharmacometrics Syst Pharmacol; 2013 Jun; 2(6):e49. PubMed ID: 23887745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural identifiability and indistinguishability analyses of the minimal model and a euglycemic hyperinsulinemic clamp model for glucose-insulin dynamics.
    Chin SV; Chappell MJ
    Comput Methods Programs Biomed; 2011 Nov; 104(2):120-34. PubMed ID: 20851494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural identifiability analyses of candidate models for in vitro Pitavastatin hepatic uptake.
    Grandjean TR; Chappell MJ; Yates JW; Evans ND
    Comput Methods Programs Biomed; 2014 May; 114(3):e60-9. PubMed ID: 23870173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic approach for doing an a priori identifiability study of dynamical nonlinear models.
    Verdière N; Orange S
    Math Biosci; 2019 Feb; 308():105-113. PubMed ID: 30562488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonlinear mixed-effects models for pharmacokinetic data analysis: assessment of the random-effects distribution.
    Drikvandi R
    J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):223-232. PubMed ID: 28194555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations.
    Eudy RJ; Riggs MM; Gastonguay MR
    AAPS J; 2015 Sep; 17(5):1280-4. PubMed ID: 26077506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifiability of fractional order systems using input output frequency contents.
    Nazarian P; Haeri M; Tavazoei MS
    ISA Trans; 2010 Apr; 49(2):207-14. PubMed ID: 20005512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing robustness of designs for random effects parameters for nonlinear mixed-effects models.
    Duffull SB; Hooker AC
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):611-616. PubMed ID: 29064062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On Parameter Identifiability in Network-Based Epidemic Models.
    Kiss IZ; Simon PL
    Bull Math Biol; 2023 Jan; 85(3):18. PubMed ID: 36705777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Classical structural identifiability methodology applied to low-dimensional dynamic systems in receptor theory.
    White C; Rottschäfer V; Bridge L
    J Pharmacokinet Pharmacodyn; 2024 Feb; 51(1):39-63. PubMed ID: 37389744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.